The company is expanding its contract development and manufacturing services for parenteral drugs to global customers.
Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation, announced on Oct. 31, 2022 that it is expanding its contract development and manufacturing services for parenteral drugs to customers outside of Japan. The contract and development manufacturing organization (CDMO) offers end-to-end services with pre-filled syringe (PFS) design, molding, drug preparation, filling, assembly, and final packaging for biotech drugs and small molecules.
The expanded services would include early development stage to large-scale commercial production for global pharmaceutical customers, including assembly of PFS with devices such as autoinjectors and needle safety devices. The company would also offer customers global regulatory submissions support.
“I am excited for what the future holds for Terumo as we are in a unique position being able to offer an integrated solution of primary container, fill and finish capability, and device assembly, in addition to our traditional offering of injection, primary container, and infusion therapy devices,” said Marco Chiadò Piat, president of Terumo Pharmaceutical Solutions, in a press release.
Terumo will be showcasing the new global CDMO service at CPHI Frankfurt from Nov. 1–3, 2022.
Source: Terumo
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.